Relmada Therapeutics Inc (NASDAQ:RLMD) is among the best psychedelic stocks to buy in 2026. The company has several potential drugs at various stages of development. Its psychedelic drug candidate REL-P11 has completed a Phase 1 safety study as a potential treatment for metabolic diseases. REL-P11 is based on a formulation of a hallucinogenic substance called psilocybin. The company’s other drug candidate NDV-01 is being developed as a treatment for an aggressive form of bladder cancer.
Pressmaster/Shutterstock.com
On March 9, Mizuho reiterated its Outperform rating and $10 price target on Relmada Therapeutics stock. The firm pointed to the Phase 2 trial results for NDV-01 for its renewed bullish stance on the stock. The 12-month data from the study showed positive results. When it comes to assessing durability in a clinical program, a 12-month trial data readout is considered the gold standard. Moreover, this timeframe is also the FDA benchmark when it comes to evaluating efficacy in the form of bladder cancer that NDV-01 targets.
According to Mizuho, the 12-month response rate could put NDV-01 ahead compared to rival bladder cancer treatments in development or on the market.
Relmada Therapeutics Inc (NASDAQ:RLMD) is an American clinical-stage biotechnology company based in Florida. It focuses on the development of treatments for various conditions, including bladder cancer and metabolic diseases. Its portfolio includes at least drug candidates in Phase 2 trials, and at least one in a Phase 1 stage.
While we acknowledge the potential of RLMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
